Clinical trial
Repinotan in Patients With Acute Ischemic Stroke
NCT00044915 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00044915 |
|---|---|
| Title | Repinotan in Patients With Acute Ischemic Stroke |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stroke, Acute Ischemic Stroke |
| Intervention type | Drug |
| Interventions | Repinotan HCl (BAYX3702), Placebo |
| Enrollment | 782 |
| Start date | Dec 1, 2000 |
| Completion | Sep 1, 2004 |
| First posted | Sep 9, 2002 |
| Last update posted | Jun 12, 2009 |
| Countries | Australia, Austria, Belgium, Canada, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Spain and 3 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: